Annexon's ANX005 offers improvement in Phase III GBS trial [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
The placebo-controlled, randomised trial enrolled 241 patients in Bangladesh and the Philippines to assess two 30mg/kg and 75mg/kg doses of of ANX005. According to the findings, the trial met its primary endpoint at week eight for the 30mg/kg dose, demonstrating a 2.4-fold improvement on the GBS-disability scale. The 30mg/kg dose also showed significant improvements on secondary endpoints, such as muscle strength and reduced dependency on artificial ventilation. Patients treated with ANX005 30mg/kg experienced a median reduction of 28 days on artificial ventilation by week 26, and were able to walk independently 31 days sooner than those taking the placebo. In addition, an early reduction in serum levels of neurofilament light chain, a biomarker of nerve damage, was observed. Both doses of ANX005 showed well-tolerated safety and tolerability profiles, without any new safety concerns identified. Adverse events were predominantly mild to moderate, with infusion-related reac
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Huntington's Disease Pipeline Research 2024: Insights About 20+ Companies and 25+ Pipeline Drugs - Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual MeetingGlobeNewswire
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual MeetingGlobeNewswire
ANNX
Earnings
- 5/13/24 - Beat
ANNX
Sec Filings
- 6/25/24 - Form 8-K
- 6/12/24 - Form 8-K
- 6/7/24 - Form 4
- ANNX's page on the SEC website